
## Sylvie Fauconnet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6052194/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells. Journal of Biological Chemistry, 2002, 277, 23534-23543.	3.4	99
2	N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors. Clinical Cancer Research, 2006, 12, 2780-2787.	7.0	96
3	Aâ€FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. International Journal of Cancer, 2009, 124, 1820-1828.	5.1	56
4	Expression of E-Cadherin and α-,β-,γ-Catenins in Patients With Bladder Cancer. American Journal of Clinical Pathology, 2006, 125, 119-126.	0.7	54
5	The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Experimental Cell Research, 2007, 313, 3239-3250.	2.6	32
6	Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncology Reports, 2009, 21, 1495-504.	2.6	29
7	The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL. PLoS ONE, 2011, 6, e28354.	2.5	27
8	Insights on distinct pathways of thiazolidinediones (PPARγ ligand)â€promoted apoptosis in TRAILâ€sensitive or â€resistant malignant urothelial cells. International Journal of Cancer, 2010, 127, 1769-1784.	5.1	19
9	Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells. Cellular Signalling, 2001, 13, 585-591.	3.6	17
10	Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. BMC Cancer, 2018, 18, 1239.	2.6	16
11	Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. Oncotarget, 2017, 8, 107744-107762.	1.8	13
12	Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure. Molecular and Cellular Biochemistry, 2020, 471, 113-127.	3.1	11
13	Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells. Tumor Biology, 2016, 37, 14789-14802.	1.8	9
14	The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. Cellular Signalling, 2014, 26, 433-443.	3.6	6